N-Power Medicine and VieCure announced a strategic partnership to bring N-Power Medicine’s proprietary Kaleido Registry to the VieCure network.
Through this collaboration, VieCure’s community oncology practices will gain access to both VieCure’s Halo Intelligence Platform and N-Power’s next-generation infrastructure, including its always-on Prospective External Control Arm (ProECA) platform. This model enables more community oncology practices to incorporate cutting-edge research into patient treatment plans while delivering precision medicine insights directly at the point of care.
The collaboration addresses a critical gap in cancer drug development, where fewer than 5% of adult cancer patients participate in clinical trials – often due to limited access in community settings where 85% of patients receive care. VieCure's advanced AI-enabled oncology intelligence platform and N-Power's prospective, consented, clinical data model create a powerful ecosystem that accelerates precision medicine delivery and broadens access to clinical trials in the community.
N-Power's Kaleido Registry is a first-of-its-kind, AI-enabled, human-in-the-loop data engine that prospectively captures clinical trial-grade data at the point of care, before treatment decisions are made. Through this partnership, community oncologists in the VieCure network can access real-time clinical trial opportunities and precision medicine insights directly within existing workflows, providing oncologists with immediate recommendations for both treatment optimization and clinical trial eligibility at the moment of care decision-making.
Visit VieCure for more news
